Postoperative adjuvant targeted therapy for non-small cell lung cancer / 国际肿瘤学杂志
Journal of International Oncology
;
(12): 240-243, 2020.
Article
Dans Chinois
| WPRIM
| ID: wpr-863468
ABSTRACT
As one of the main methods of postoperative adjuvant therapy for non-small cell lung cancer (NSCLC) patients, the clinical effect of platinum-containing dual-drug chemotherapy has reached a ceiling effect and it is difficult to further improve the survival of patients with NSCLC. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors have become the standard first-line treatment for advanced NSCLC with EGFR mutation, but its value as postoperative adjuvant therapy is far to be investigated. Some studies have been carried out in this field in recent years.
Texte intégral:
Disponible
Indice:
WPRIM (Pacifique occidental)
langue:
Chinois
Texte intégral:
Journal of International Oncology
Année:
2020
Type:
Article
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS